Company: FTII
Filing Date: 2025-02-14
Form Type: S-4
Source: 0001493152-25-006997
Chunk: 376

Company: FutureTech II Acquisition Corp.
Filing Date: 2025-02-14
Form: S-4
Chunk 376
---
 they do not address the underlying root cause of the disease — namely a blood clot in one or more of the retinal veins of the eye. As such, we do not view anti-VEGF therapy as competitive to our Reflow RVO TMproduct candidate. To a lesser degree, laser photocoagulation is used in the treatment of RVO. This therapeutic approach is used to seal off leaking blood vessels and slow the growth of abnormal blood vessels. Laser photocoagulation helps reduce hemorrhaging and growth of new blood vessels, but similar to anti-VEGF therapy, does not address the actual cause of RVO. As a result, most RVO patients that receive anti-VEGF and/or laser photocoagulation treatment regimens will continue to exhibit a decline in visual acuity over time. To our knowledge, Reflow RVO TMis the only therapeutic approach under development that is designed to treat the actual cause of the disease.

| 202 |

LBI-101 — Soft Tissue Replacement and Reconstruction Competitors

The potential for soft tissue augmentation technology cuts through numerous markets in plastic surgery, dermatology, oral and maxillofacial surgery and general traumatic and reconstructive surgery. LBI-101 can be used in clinical applications where fat grafting is currently used in addition to smaller volume fillers for aesthetic applications. The U.S. market size for these applications is significant with the cosmetic market alone reaching as much as $13 billion annually. 16The tissue filler market for example is over $2 billion 17and includes hyaluronic acid based products such as Juvederm that is sold by Allergan/AbbVie and particle- based fillers such as Sculptra sold by Galderma. Reconstruction applications that have significant markets include lumpectomy/breast reconstruction (137,000 procedures per year), maxillofacial reconstruction (256,000 per year), and laceration repair (386,000 per year). 18Many synthetic breast implants require additional soft tissue reconstruction procedures that include fat grafting and lumpectomies are treated today with fat grafting or synthetic implants.

Biological scaffolds in injectable forms, created from allograft or xenogeneic ECM, are used for wound healing applications as is the case for Matristem sold by Integra (formerly Acell). The only injectable biologic derived from adipose, Renuva, is sold by the Musculoskeletal Tissue Foundation.

LBI-201 — Aureva Pulse Competitors